CLIA Categorization Duties Transfer To FDA From CDC Under Negotiation
This article was originally published in The Gray Sheet
Executive Summary
Discussions are under way between FDA and the Centers for Disease Control and Prevention that could result in FDA recouping responsibility from CDC for categorization of in vitro diagnostics under the Clinical Laboratory Improvement Amendments of 1988, the Health Industry Manufacturers Association reports.